Business
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n\nContinued clinical execution across TRACTr programs JANX007 and JANX008\n\n\nJANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC)\n\n\n\nJANX008 enrolling expansion cohorts in defined tumor settings\n\n\n\n\n\n\nInitiated Phase 1 study of JANX011 in healthy volunteers\n\n\n\nEntered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors\n\n\n\nAppointment of William Go, M.D., Ph.D., as Chief Medical Officer\n\n\n\nStrong year-end cash position supporting continued pipeline execution\n\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.\n\n\n“The past year marked a period of significant execution and progress for Janux as we continued to translate the promise of our tumor-activated platform into meaningful clinical and strategic advances. Recent JANX007 clinical results demonstrate clinical activity and a consistent and predictable safety profile in mCRPC and support continued advancement in taxane-naïve patients as well as other expansion cohorts,” said David Campbell, Ph.D., President and CEO of Janux.\n\n\n“In early 2026, we announced a collaboration with Bristol Myers Squibb that provides near-term capital and further validates the potential of our platform. We also continue to strengthen our team to support the next phase of clinical and pipeline growth. With additional product candidates entering the clinic in 2026, we believe Janux is well positioned to execute on our clinical strategy and continue to build long-term value for patients and shareholders.”\n\n\nBUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS:\n\n\nClinical & Pipeline Progress\n\n\n\nJanux presented updated interim Phase 1 data for JANX007 (PSMA-TRACTr) in December 2025. As of the October 15, 2025 data cutoff, 109 patients had been treated across Phase 1 cohorts:\n\n\nDurable clinical activity was observed across both once-weekly (QW) and every-two-week (Q2W) cohorts, with median radiographic progression-free survival (rPFS) ranging from 7.9 to 8.9 mo...